GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Quick Ratio

EV Biologics (EV Biologics) Quick Ratio : 3.11 (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. EV Biologics's quick ratio for the quarter that ended in Dec. 2017 was 3.11.

EV Biologics has a quick ratio of 3.11. It generally indicates good short-term financial strength.

The historical rank and industry rank for EV Biologics's Quick Ratio or its related term are showing as below:

YECO's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.53
* Ranked among companies with meaningful Quick Ratio only.

EV Biologics Quick Ratio Historical Data

The historical data trend for EV Biologics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Quick Ratio Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Quick Ratio
1.04 1.93 0.86 0.41 0.29

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.35 0.32 0.29 3.11

Competitive Comparison of EV Biologics's Quick Ratio

For the Biotechnology subindustry, EV Biologics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where EV Biologics's Quick Ratio falls into.



EV Biologics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

EV Biologics's Quick Ratio for the fiscal year that ended in Jun. 2017 is calculated as

Quick Ratio (A: Jun. 2017 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(8.913-0.209)/29.559
=0.29

EV Biologics's Quick Ratio for the quarter that ended in Dec. 2017 is calculated as

Quick Ratio (Q: Dec. 2017 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(52.049-0.125)/16.719
=3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics  (OTCPK:YECO) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


EV Biologics Quick Ratio Related Terms

Thank you for viewing the detailed overview of EV Biologics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Unveils NFT Dividend Warrant

By ACCESSWIRE ACCESSWIRE 07-26-2021

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

By ACCESSWIRE ACCESSWIRE 08-12-2021

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021

EV Biologics is now Pink Current

By ACCESSWIRE ACCESSWIRE 06-14-2021

EV Biologics Updates on NFT Warrant Dividend Distribution

By ACCESSWIRE ACCESSWIRE 08-30-2021

EV Biologics Generates Mesenchymal Stem Cell Lines

By ACCESSWIRE ACCESSWIRE 02-21-2023

EV Biologics NFT Dividend Warrant Date

By ACCESSWIRE ACCESSWIRE 07-30-2021

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021